Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
6341498
Reference Type
Journal Article
Title
Utility of the platelet function analyser (PFA-100/200) for exclusion or detection of von Willebrand disease: A study 22 years in the making
Author(s)
Favaloro, EJ
Year
2020
Is Peer Reviewed?
1
Journal
Thrombosis Research
ISSN:
0049-3848
Publisher
Elsevier
Volume
188
Issue
Elsevier
Page Numbers
17-24
Language
English
PMID
32036157
DOI
10.1016/j.thromres.2020.01.029
URL
http://www.sciencedirect.com/science/article/pii/S0049384820300384
Exit
Abstract
Introduction von Willebrand disease (VWD) is the most common inherited bleeding disorder and may alternatively arise as an acquired condition (AVWS). These represent deficiency and/or defects in von Willebrand factor (VWF). Closure times (CTs) obtained from the platelet function analyser (PFA) are highly sensitive to both VWD/AVWS. The current study has evaluated the utility of the PFA-100/-200 to exclude or detect laboratory identified VWD. Materials and methods An evaluation of the success or otherwise of prospective PFA testing to help exclude or detect VWD using data from a locally maintained database. This database contains patient information, results of PFA testing, results of VWF testing, platelet count and hematocrit, and additional information, for a current total of 3678 entries representing over 2 decades of testing. Results According to selection criteria, a total of 142 samples were identified as derived from patients with VWD. All but one of these were also identified to have abnormal PFA CTs. Additional data sets of patients with low VWF (n = 137), or borderline normal VWF (n = 163) were also identified, as well as patients with thrombocytopenia and/or low hematocrit (n = 487). In these cohorts, PFA CTs were often (but not always) abnormal. There was a strong association between VWF test parameter values and PFA CTs. Additional study samples comprised cases with normal VWF parameters but prolonged CTs (n = 594), as well as cases with normal VWF and normal CTs (n = 1292), permitting calculation of sensitivity of abnormal PFA for VWD (99.3%), as well as specificity (68.5%), negative predictive value (99.9%) and positive predictive value (19.2%), for a prevalence of 7.0%. Comparatively, normal PFA CTs were better able to exclude VWD than normal test results for individual VWF parameters. Conclusion This study reports on an evaluation of PFA CTs for identification or exclusion of VWD. In our dataset, representing over 22 years of experience, normal PFA CTs were able to predict absence of VWD with higher sensitivity than individual VWF test results.
Keywords
von Willebrand disease; von Willebrand factor; Platelet function analyser; PFA-100; PFA-200
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity